Author

Qian-Ming Du

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Disruption of p62 ubiquitination by α-methylene-γ-butyrolactone enhances Keap1 lysosomal degradation for ulcerative colitis therapy.

Ulcerative colitis (UC) is an intestinal inflammatory disorder primarily driven by M1 macrophage activation and oxidative stress. p62/Sequestosome-1, a multifunctional autophagy adaptor protein, plays a critical role in regulating autophagy and inflammation. α-Methylene-γ-butyrolactone (αMγB), a conserved structural mo...

Ke-Gang Linghu, Da-Song Wang, Tian Zhang et al. · Redox Biology · 0 citations

Open access Sep 2026

Boosting oral bioavailability of taraxasterol via a nanocrystal-mucoadhesive micropatch platform for potent multi-mechanistic protection against drug-induced liver injury

Drug-induced liver injury (DILI) is a serious adverse reaction with limited therapeutic options. Taraxasterol (TAS), a natural triterpenoid with hepatoprotective potential, suffers from poor aqueous solubility and low oral bioavailability, hindering its clinical application. Here, we develop an integrated oral delivery...

Zi-Min Cai, Huan-Qing Zhao, Ming-Yu Wei et al. · Materials Today Bio · 0 citations

Sep 2026

Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy

Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1/HDAC dual inhibitors as a single-molecule strategy for cancer therapy. Through sy...

Zhi-Sheng Zhang, Xuan Zhang, Yi-Nan Jiang et al. · Journal of Medicinal Chemist... · 0 citations